메뉴 건너뛰기




Volumn 32, Issue 5, 2014, Pages 443-455

Is individualized medicine more cost-effective? A systematic review

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BLOOD CLOTTING FACTOR 5 LEIDEN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHEMOKINE RECEPTOR CCR5; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DNA GLYCOSYLASE MUTY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCURONOSYLTRANSFERASE; HLA B ANTIGEN; INTERLEUKIN 1; K RAS PROTEIN; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; PANTOTHENATE KINASE 2; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ1; SODIUM CHANNEL NAV1.5; THIOPURINE METHYLTRANSFERASE; TROPONIN I; TROPONIN T; VIRUS DNA;

EID: 84902303965     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0143-0     Document Type: Review
Times cited : (59)

References (78)
  • 2
    • 84870526559 scopus 로고    scopus 로고
    • Personalized oncology: Recent advances and future challenges
    • Kalia M. Personalized oncology: recent advances and future challenges. Metab Clin Exp. 2013;62 Suppl 1:S11-4.
    • (2013) Metab Clin Exp , vol.62 , Issue.SUPPL. 1
    • Kalia, M.1
  • 3
    • 78650168711 scopus 로고    scopus 로고
    • Further opportunities for cost reduction of medical care
    • Malach M, Baumol WJ. Further opportunities for cost reduction of medical care. J Commun Health. 2010;35(6):561-71.
    • (2010) J Commun Health , vol.35 , Issue.6 , pp. 561-571
    • Malach, M.1    Baumol, W.J.2
  • 4
    • 84871217315 scopus 로고    scopus 로고
    • Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR personalized medicine special interest group
    • Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health. 2012;15(8):1162-71.
    • (2012) Value Health , vol.15 , Issue.8 , pp. 1162-1171
    • Faulkner, E.1    Annemans, L.2    Garrison, L.3    Helfand, M.4    Holtorf, A.P.5    Hornberger, J.6
  • 6
    • 77953315728 scopus 로고    scopus 로고
    • President's Council of Advisors on Science and Technology. Accessed 10 Nov 2013
    • President's Council of Advisors on Science and Technology. Priorities for Personalized Medicine; 2008. http://www.whitehouse.gov/files/documents/ostp/ PCAST/pcast-report-v2.pdf. Accessed 10 Nov 2013.
    • (2008) Priorities for Personalized Medicine
  • 7
    • 84856247119 scopus 로고    scopus 로고
    • Accessed 4 Jan 2012
    • Personalized Medicine Coalition. The case for personalized medicine. 3rd ed; 2011. http://www.personalizedmedicinecoalition.org/sites/default/files/ files/Case-for-PM-3rd-edition.pdf. Accessed 4 Jan 2012.
    • (2011) The Case for Personalized Medicine. 3rd Ed
  • 8
    • 77951869318 scopus 로고    scopus 로고
    • Personalized medicine and genomics: Challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities
    • Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making. 2010;30(3):328-40.
    • (2010) Med Decis Making , vol.30 , Issue.3 , pp. 328-340
    • Conti, R.1    Veenstra, D.L.2    Armstrong, K.3    Lesko, L.J.4    Grosse, S.D.5
  • 9
    • 3042819551 scopus 로고    scopus 로고
    • The role of cost-effectiveness analysis in the era of pharmacogenomics
    • DOI 10.2165/00019053-200422080-00001
    • Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. PharmacoEconomics. 2004;22(8):481-93. (Pubitemid 38858292)
    • (2004) PharmacoEconomics , vol.22 , Issue.8 , pp. 481-493
    • Flowers, C.R.1    Veenstra, D.2
  • 11
    • 27644465790 scopus 로고    scopus 로고
    • Economic analyses of human genetics services: A systematic review
    • DOI 10.1097/01.GIM.0000182467.79495.e2
    • Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: a systematic review. Genet Med. 2005;7(8):519-23. (Pubitemid 41566478)
    • (2005) Genetics in Medicine , vol.7 , Issue.8 , pp. 519-523
    • Carlson, J.J.1    Henrikson, N.B.2    Veenstra, D.L.3    Ramsey, S.D.4
  • 12
    • 11044228905 scopus 로고    scopus 로고
    • A systematic review of cost-effectiveness analyses of pharmacogenomic interventions
    • DOI 10.1517/14622416.5.8.1139
    • Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics. 2004;5(8):1139-49. (Pubitemid 40045254)
    • (2004) Pharmacogenomics , vol.5 , Issue.8 , pp. 1139-1149
    • Phillips, K.A.1    Van Bebber, S.L.2
  • 13
    • 45749090093 scopus 로고    scopus 로고
    • Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: A systematic review on content and adherence to guidelines
    • DOI 10.2165/00019053-200826070-00005
    • Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics. 2008;26(7):569-87. (Pubitemid 351871553)
    • (2008) PharmacoEconomics , vol.26 , Issue.7 , pp. 569-587
    • Vegter, S.1    Boersma, C.2    Rozenbaum, M.3    Wilffert, B.4    Navis, G.5    Postma, M.J.6
  • 14
    • 77957995461 scopus 로고    scopus 로고
    • Cost effectiveness of pharmacogenomics: A critical and systematic review
    • Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. PharmacoEconomics. 2010;28(11):1001-13.
    • (2010) PharmacoEconomics , vol.28 , Issue.11 , pp. 1001-1013
    • Wong, W.B.1    Carlson, J.J.2    Thariani, R.3    Veenstra, D.L.4
  • 15
    • 33749155617 scopus 로고    scopus 로고
    • Genetic screening by DNA technology: A systematic review of health economic evidence
    • DOI 10.1017/S0266462306051221, PII S0266462306051221
    • Rogowski W. Genetic screening by DNA technology. A systematic review of health economic evidence. Int J Technol Assess Health Care. 2006;22(3):327-37. (Pubitemid 44469439)
    • (2006) International Journal of Technology Assessment in Health Care , vol.22 , Issue.3 , pp. 327-337
    • Rogowski, W.1
  • 16
    • 33845487333 scopus 로고    scopus 로고
    • Current impact of gene technology on healthcare. A map of economic assessments
    • DOI 10.1016/j.healthpol.2006.03.009, PII S0168851006000698
    • Rogowski W. Current impact of gene technology on healthcare. A map of economic assessments. Health Policy. 2007;5(80):340-57. (Pubitemid 44914099)
    • (2007) Health Policy , vol.80 , Issue.2 , pp. 340-357
    • Rogowski, W.1
  • 17
    • 84902325823 scopus 로고    scopus 로고
    • Accessed 5 Jan 2012
    • National Center for Biotechnology Information. Individualized medicine. 2010. http://www.ncbi.nlm.nih.gov/mesh/68057285. Accessed 5 Jan 2012.
    • (2010) Individualized Medicine
  • 19
    • 84902343940 scopus 로고    scopus 로고
    • Medicine UNLo. Accessed 9 Oct 2013
    • Medicine UNLo. What is genetic testing?; 2013. http://ghr.nlm.nih.gov/ handbook/testing/genetictesting. Accessed 9 Oct 2013.
    • (2013) What Is Genetic Testing?
  • 20
    • 33947605979 scopus 로고    scopus 로고
    • Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
    • DOI 10.1200/JCO.2006.06.4220
    • Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007;25(6):625-33. (Pubitemid 350002916)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.6 , pp. 625-633
    • Liberato, N.L.1    Marchetti, M.2    Barosi, G.3
  • 21
    • 33947584307 scopus 로고    scopus 로고
    • A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
    • DOI 10.1200/JCO.2006.06.3081
    • Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007;25(6):634-41. (Pubitemid 350002917)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.6 , pp. 634-641
    • Kurian, A.W.1    Thompson, R.N.2    Gaw, A.F.3    Arai, S.4    Ortiz, R.5    Garber, A.M.6
  • 23
    • 84902329169 scopus 로고    scopus 로고
    • Accessed 2 Oct 2012
    • Centers for Medicare & Medicaid Services. Draft ICD-10-CM/PCS MS-DRGv28 Definitions Manual. http://www.cms.gov/icd10manual/fullcode-cms/P0001. html. Accessed 2 Oct 2012.
    • Draft ICD-10-CM/PCS MS-DRGv28 Definitions Manual
  • 24
    • 70349925974 scopus 로고    scopus 로고
    • 30 Years of pharmaceutical cost-utility analyses: Growth, diversity and methodological improvement
    • Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. PharmacoEconomics. 2009;27(10):861-72.
    • (2009) PharmacoEconomics , vol.27 , Issue.10 , pp. 861-872
    • Neumann, P.J.1    Fang, C.H.2    Cohen, J.T.3
  • 25
    • 84902318962 scopus 로고    scopus 로고
    • Accessed 27 June 2012
    • Organization for Economic Co-operation and Development. 2008 PPP Benchmark results; 2008. http://stats.oecd.org/. Accessed 27 June 2012.
    • (2008) 2008 PPP Benchmark Results
  • 26
    • 84902317340 scopus 로고    scopus 로고
    • Accessed 27 June 2012
    • Organization for Economic Co-operation and Development. Consumer Prices (MEI); 2012. http://stats.oecd.org/. Accessed 27 June 2012.
    • (2012) Consumer Prices (MEI)
  • 27
    • 78650801916 scopus 로고    scopus 로고
    • Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population
    • (Phila)
    • Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila). 2011;4(1):9-22.
    • (2011) Cancer Prev Res , vol.4 , Issue.1 , pp. 9-22
    • Dinh, T.A.1    Rosner, B.I.2    Atwood, J.C.3    Boland, C.R.4    Syngal, S.5    Vasen, H.F.6
  • 28
    • 77149122082 scopus 로고    scopus 로고
    • The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer
    • Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12(2):93-104.
    • (2010) Genet Med , vol.12 , Issue.2 , pp. 93-104
    • Mvundura, M.1    Grosse, S.D.2    Hampel, H.3    Palomaki, G.E.4
  • 29
    • 79960604164 scopus 로고    scopus 로고
    • Strategies to identify the Lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis
    • Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155(2):69-79.
    • (2011) Ann Intern Med , vol.155 , Issue.2 , pp. 69-79
    • Ladabaum, U.1    Wang, G.2    Terdiman, J.3    Blanco, A.4    Kuppermann, M.5    Boland, C.R.6
  • 30
    • 0142031151 scopus 로고    scopus 로고
    • An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer
    • DOI 10.1097/01.GIM.0000086626.03082.B5
    • Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med. 2003;5(5):353-63. (Pubitemid 37264984)
    • (2003) Genetics in Medicine , vol.5 , Issue.5 , pp. 353-363
    • Ramsey, S.D.1    Burke, W.2    Clarke, L.3
  • 31
    • 0035899935 scopus 로고    scopus 로고
    • Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer
    • Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001;135(8 Pt 1):577-88. (Pubitemid 33010193)
    • (2001) Annals of Internal Medicine , vol.135 , Issue.8 II , pp. 577-588
    • Ramsey, S.D.1    Clarke, L.2    Etzioni, R.3    Higashi, M.4    Berry, K.5    Urban, N.6
  • 34
    • 60349111615 scopus 로고    scopus 로고
    • Cost-effectiveness of testing for breast cancer susceptibility genes
    • Holland ML, Huston A, Noyes K. Cost-effectiveness of testing for breast cancer susceptibility genes. Value Health. 2009;12(2):207-16.
    • (2009) Value Health , vol.12 , Issue.2 , pp. 207-216
    • Holland, M.L.1    Huston, A.2    Noyes, K.3
  • 35
    • 0035958252 scopus 로고    scopus 로고
    • Policy analysis of cervical cancer screening strategies in low-resource settings: Clinical benefits and cost-effectiveness
    • Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285(24):3107-15. (Pubitemid 32586089)
    • (2001) Journal of the American Medical Association , vol.285 , Issue.24 , pp. 3107-3115
    • Goldie, S.J.1    Kuhn, L.2    Denny, L.3    Pollack, A.4    Wright, T.C.5
  • 36
    • 0035899935 scopus 로고    scopus 로고
    • Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer
    • Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001;135(8 Part 1):577-88. (Pubitemid 33010193)
    • (2001) Annals of Internal Medicine , vol.135 , Issue.8 II , pp. 577-588
    • Ramsey, S.D.1    Clarke, L.2    Etzioni, R.3    Higashi, M.4    Berry, K.5    Urban, N.6
  • 37
    • 84860174889 scopus 로고    scopus 로고
    • A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy
    • (British Cardiac Society)
    • Ingles J, McGaughran J, Scuffham PA, Atherton J, Semsarian C. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart (British Cardiac Society). 2012;98(8):625-30.
    • (2012) Heart , vol.98 , Issue.8 , pp. 625-630
    • Ingles, J.1    McGaughran, J.2    Scuffham, P.A.3    Atherton, J.4    Semsarian, C.5
  • 38
    • 77957374284 scopus 로고    scopus 로고
    • Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?
    • Gordon LG, Hirst NG, Young RP, Brown PM. Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness? Cost Eff Resour Alloc. 2010;8:18.
    • (2010) Cost Eff Resour Alloc , vol.8 , pp. 18
    • Gordon, L.G.1    Hirst, N.G.2    Young, R.P.3    Brown, P.M.4
  • 39
    • 0036962281 scopus 로고    scopus 로고
    • The cost-effectiveness of interleukin-1 genetic testing for periodontal disease
    • DOI 10.1902/jop.2002.73.12.1474
    • Higashi MK, Veenstra DL, del Aguila M, Hujoel P. The cost-effectiveness of interleukin-1 genetic testing for periodontal disease. J Periodontol. 2002;73(12):1474-84. (Pubitemid 36131619)
    • (2002) Journal of Periodontology , vol.73 , Issue.12 , pp. 1474-1484
    • Higashi, M.K.1    Veenstra, D.L.2    Del, A.M.3    Hujoel, P.4
  • 40
    • 84856146284 scopus 로고    scopus 로고
    • Head-to-head comparison of the 70-gene signature versus the 21-gene assay: Cost-effectiveness and the effect of compliance
    • Retel VP, Joore MA, van Harten WH. Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance. Breast Cancer Res Treat. 2012;131(2):627-36.
    • (2012) Breast Cancer Res Treat , vol.131 , Issue.2 , pp. 627-636
    • Retel, V.P.1    Joore, M.A.2    Van Harten, W.H.3
  • 41
    • 77951938304 scopus 로고    scopus 로고
    • Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
    • Retel VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Harten WH. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer. 2010;46(8):1382-91.
    • (2010) Eur J Cancer , vol.46 , Issue.8 , pp. 1382-1391
    • Retel, V.P.1    Joore, M.A.2    Knauer, M.3    Linn, S.C.4    Hauptmann, M.5    Harten, W.H.6
  • 42
    • 77952605337 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer
    • Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist. 2010;15(5):457-65.
    • (2010) Oncologist , vol.15 , Issue.5 , pp. 457-465
    • Tsoi, D.T.1    Inoue, M.2    Kelly, C.M.3    Verma, S.4    Pritchard, K.I.5
  • 43
    • 79957823551 scopus 로고    scopus 로고
    • Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer
    • Chen E, Tong KB, Malin JL. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer. Am J Manage Care. 2010;16(12):e333-42.
    • (2010) Am J Manage Care , vol.16 , Issue.12
    • Chen, E.1    Tong, K.B.2    Malin, J.L.3
  • 44
    • 52949084374 scopus 로고    scopus 로고
    • Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan
    • Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res Treat. 2008;112(1):175-87.
    • (2008) Breast Cancer Res Treat , vol.112 , Issue.1 , pp. 175-187
    • Kondo, M.1    Hoshi, S.L.2    Ishiguro, H.3    Yoshibayashi, H.4    Toi, M.5
  • 45
    • 84863717098 scopus 로고    scopus 로고
    • Economic evaluation of the 70-gene prognosis-signature (MammaPrint(R)) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan
    • Kondo M, Hoshi SL, Ishiguro H, Toi M. Economic evaluation of the 70-gene prognosis-signature (MammaPrint(R)) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan. Breast Cancer Res Treat. 2012;133(2):759-68.
    • (2012) Breast Cancer Res Treat , vol.133 , Issue.2 , pp. 759-768
    • Kondo, M.1    Hoshi, S.L.2    Ishiguro, H.3    Toi, M.4
  • 46
    • 23744459918 scopus 로고    scopus 로고
    • Gene expression profiling and breast cancer care: What are the potential benefits and policy implications?
    • DOI 10.1097/01.GIM.0000170776.31248.75
    • Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med. 2005;7(6):380-9. (Pubitemid 41139621)
    • (2005) Genetics in Medicine , vol.7 , Issue.6 , pp. 380-389
    • Oestreicher, N.1    Ramsey, S.D.2    Linden, H.M.3    McCune, J.S.4    Van't, V.L.J.5    Burke, W.6    Veenstra, D.L.7
  • 47
    • 79960802694 scopus 로고    scopus 로고
    • Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer
    • Vanderlaan BF, Broder MS, Chang EY, Oratz R, Bentley TG. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. Am J Manage Care. 2011;17(7):455-64.
    • (2011) Am J Manage Care , vol.17 , Issue.7 , pp. 455-464
    • Vanderlaan, B.F.1    Broder, M.S.2    Chang, E.Y.3    Oratz, R.4    Bentley, T.G.5
  • 48
    • 18444374426 scopus 로고    scopus 로고
    • Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer
    • Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymphnode-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manage Care. 2005;11(5):313-24. (Pubitemid 40646936)
    • (2005) American Journal of Managed Care , vol.11 , Issue.5 , pp. 313-324
    • Hornberger, J.1    Cosler, L.E.2    Lyman, G.H.3
  • 49
    • 84863723973 scopus 로고    scopus 로고
    • Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
    • Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat. 2012;133(3):1115-23.
    • (2012) Breast Cancer Res Treat , vol.133 , Issue.3 , pp. 1115-1123
    • Lamond, N.W.1    Skedgel, C.2    Rayson, D.3    Lethbridge, L.4    Younis, T.5
  • 50
    • 77954257827 scopus 로고    scopus 로고
    • Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization
    • Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health. 2010;13(4):381-7.
    • (2010) Value Health , vol.13 , Issue.4 , pp. 381-387
    • Klang, S.H.1    Hammerman, A.2    Liebermann, N.3    Efrat, N.4    Doberne, J.5    Hornberger, J.6
  • 51
    • 84855484712 scopus 로고    scopus 로고
    • Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer
    • Hall PS, McCabe C, Stein RC, Cameron D. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst. 2012;104(1):56-66.
    • (2012) J Natl Cancer Inst , vol.104 , Issue.1 , pp. 56-66
    • Hall, P.S.1    McCabe, C.2    Stein, R.C.3    Cameron, D.4
  • 52
    • 58149522113 scopus 로고    scopus 로고
    • Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa
    • Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol. 2009;112(2):377-83.
    • (2009) Gynecol Oncol , vol.112 , Issue.2 , pp. 377-383
    • Vijayaraghavan, A.1    Efrusy, M.2    Lindeque, G.3    Dreyer, G.4    Santas, C.5
  • 55
    • 51349117705 scopus 로고    scopus 로고
    • Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis
    • Smith KJ, Monsef BS, Ragni MV. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. Thrombosis Haemostasis. 2008;100(3):447-52.
    • (2008) Thrombosis Haemostasis , vol.100 , Issue.3 , pp. 447-452
    • Smith, K.J.1    Monsef, B.S.2    Ragni, M.V.3
  • 56
    • 34547920290 scopus 로고    scopus 로고
    • Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations
    • Nielsen M, Hes FJ, Vasen HF, van den Hout WB. Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations. BMC Med Genet. 2007;8:42.
    • (2007) BMC Med Genet , vol.8 , pp. 42
    • Nielsen, M.1    Hes, F.J.2    Vasen, H.F.3    Van Den Hout, W.B.4
  • 57
    • 58749095297 scopus 로고    scopus 로고
    • Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation
    • Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Int Med. 2009;150(2):73-83.
    • (2009) Ann Int Med , vol.150 , Issue.2 , pp. 73-83
    • Eckman, M.H.1    Rosand, J.2    Greenberg, S.M.3    Gage, B.F.4
  • 58
    • 73349093096 scopus 로고    scopus 로고
    • A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing
    • Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. PharmacoEconomics. 2010;28(1):61-74.
    • (2010) PharmacoEconomics , vol.28 , Issue.1 , pp. 61-74
    • Meckley, L.M.1    Gudgeon, J.M.2    Anderson, J.L.3    Williams, M.S.4    Veenstra, D.L.5
  • 60
    • 77949874647 scopus 로고    scopus 로고
    • Thiopurine S-methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: A pharmacogenetic cost-effectiveness analysis
    • Hagaman JT, Kinder BW, Eckman MH. Thiopurine S-methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung. 2010;188(2):125-32.
    • (2010) Lung , vol.188 , Issue.2 , pp. 125-132
    • Hagaman, J.T.1    Kinder, B.W.2    Eckman, M.H.3
  • 61
    • 70350221662 scopus 로고    scopus 로고
    • Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy
    • You JH, Tsui KK, Wong RS, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin Pharmacol Ther. 2009;86(5):540-7.
    • (2009) Clin Pharmacol Ther , vol.86 , Issue.5 , pp. 540-547
    • You, J.H.1    Tsui, K.K.2    Wong, R.S.3    Cheng, G.4
  • 62
    • 37349001289 scopus 로고    scopus 로고
    • Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: Potential impact on clinical, patient, and economic outcomes
    • DOI 10.1097/GIM.0b013e318156dd07, PII 0012581720071000000005
    • Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med. 2007;9(10):695-704. (Pubitemid 350287155)
    • (2007) Genetics in Medicine , vol.9 , Issue.10 , pp. 695-704
    • Veenstra, D.L.1    Harris, J.2    Gibson, R.L.3    Rosenfeld, M.4    Burke, W.5    Watts, C.6
  • 63
    • 58849092406 scopus 로고    scopus 로고
    • The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
    • Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health. 2009;12(1):20-7.
    • (2009) Value Health , vol.12 , Issue.1 , pp. 20-27
    • Carlson, J.J.1    Garrison, L.P.2    Ramsey, S.D.3    Veenstra, D.L.4
  • 64
    • 1542503725 scopus 로고    scopus 로고
    • HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis
    • DOI 10.1200/JCO.2004.04.158
    • Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004;22(5):854-63. (Pubitemid 41103597)
    • (2004) Journal of Clinical Oncology , vol.22 , Issue.5 , pp. 854-863
    • Elkin, E.B.1    Weinstein, M.C.2    Winer, E.P.3    Kuntz, K.M.4    Schnitt, S.J.5    Weeks, J.C.6
  • 66
    • 68949196334 scopus 로고    scopus 로고
    • When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study
    • Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology. 2009;34(10):2227-36.
    • (2009) Neuropsychopharmacology , vol.34 , Issue.10 , pp. 2227-2236
    • Perlis, R.H.1    Patrick, A.2    Smoller, J.W.3    Wang, P.S.4
  • 67
    • 80053475784 scopus 로고    scopus 로고
    • KRAS and BRAF mutation analysis in metastatic colorectal cancer: A cost-effectiveness analysis from a Swiss perspective
    • Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res. 2011;17(19):6338-46.
    • (2011) Clin Cancer Res , vol.17 , Issue.19 , pp. 6338-6346
    • Blank, P.R.1    Moch, H.2    Szucs, T.D.3    Schwenkglenks, M.4
  • 68
    • 84865560854 scopus 로고    scopus 로고
    • Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
    • Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012;56(3):850-60.
    • (2012) Hepatology , vol.56 , Issue.3 , pp. 850-860
    • Camma, C.1    Petta, S.2    Enea, M.3    Bruno, R.4    Bronte, F.5    Capursi, V.6
  • 69
    • 40149108602 scopus 로고    scopus 로고
    • Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
    • DOI 10.1093/annonc/mdm488
    • Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol. 2008;19(3):487-95. (Pubitemid 351325669)
    • (2008) Annals of Oncology , vol.19 , Issue.3 , pp. 487-495
    • Lidgren, M.1    Jonsson, B.2    Rehnberg, C.3    Willking, N.4    Bergh, J.5
  • 70
    • 84870267023 scopus 로고    scopus 로고
    • Endogenous cost-effectiveness analysis and health care technology adoption
    • Jena AB, Philipson TJ. Endogenous cost-effectiveness analysis and health care technology adoption. J Health Econ. 2013;32(1):172-80.
    • (2013) J Health Econ , vol.32 , Issue.1 , pp. 172-180
    • Jena, A.B.1    Philipson, T.J.2
  • 71
    • 84865429505 scopus 로고    scopus 로고
    • A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory
    • Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. Natl Biotechnol. 2012;29(6):613-24.
    • (2012) Natl Biotechnol , vol.29 , Issue.6 , pp. 613-624
    • Hood, L.1    Flores, M.2
  • 72
    • 33645810425 scopus 로고    scopus 로고
    • Good practice guidelines for decision-analytic modelling in health technology assessment: A review and consolidation of quality assessment
    • Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. PharmacoEconomics. 2006;24(4):355-71.
    • (2006) PharmacoEconomics , vol.24 , Issue.4 , pp. 355-371
    • Philips, Z.1    Bojke, L.2    Sculpher, M.3    Claxton, K.4    Golder, S.5
  • 74
    • 64549101706 scopus 로고    scopus 로고
    • Pharmacogenomics and public health
    • Veenstra D, Burke W. Pharmacogenomics and public health. Public Health Genomics. 2009;12(3):131-3.
    • (2009) Public Health Genomics , vol.12 , Issue.3 , pp. 131-133
    • Veenstra, D.1    Burke, W.2
  • 75
    • 64549116875 scopus 로고    scopus 로고
    • Pharmacogenomics, evidence, and the role of payers
    • Deverka PA. Pharmacogenomics, evidence, and the role of payers. Public Health Genomics. 2009;12(3):149-57.
    • (2009) Public Health Genomics , vol.12 , Issue.3 , pp. 149-157
    • Deverka, P.A.1
  • 77
    • 84877997203 scopus 로고    scopus 로고
    • Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia
    • Sorich MJ, Wiese MD, O'Shea RL, Pekarsky B. Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia. PharmacoEconomics. 2013;31(5):377-91.
    • (2013) PharmacoEconomics , vol.31 , Issue.5 , pp. 377-391
    • Sorich, M.J.1    Wiese, M.D.2    O'Shea, R.L.3    Pekarsky, B.4
  • 78
    • 79957789708 scopus 로고    scopus 로고
    • Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses
    • Ioannidis JP, Panagiotou OA. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA. 2011;305(21):2200-10.
    • (2011) JAMA , vol.305 , Issue.21 , pp. 2200-2210
    • Ioannidis, J.P.1    Panagiotou, O.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.